Quentin S.  Blackford net worth and biography

Quentin Blackford Biography and Net Worth

Quentin S. Blackford has served as our President and Chief Executive Officer since October 2021. From September 2017 to September 2021, Mr. Blackford, held various roles, the most recent one as the Chief Operating Officer, at Dexcom Inc., a company that develops, manufactures, produces, and distributes continuous glucose monitoring systems for diabetes management. From February 2009 to September 2017, Mr. Blackford was the Chief Financial Officer at Nuvasive Inc., a medical device company for minimally invasive spine surgery. From June 1999 to September 2009, Mr. Blackford was the Director of Finance and Controller of the Dental Division at Zimmer Holdings, Inc., a medical device company.

Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Paragon 28, Inc. since August 2022. He is a Certified Public Accountant (inactive) and received dual B.S. degrees in Accounting and Business Administration from Grace College.

What is Quentin S. Blackford's net worth?

The estimated net worth of Quentin S. Blackford is at least $14.46 million as of November 4th, 2024. Mr. Blackford owns 159,929 shares of iRhythm Technologies stock worth more than $14,455,982 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Blackford may own. Additionally, Mr. Blackford receives a salary of $1,420,000.00 as CEO at iRhythm Technologies. Learn More about Quentin S. Blackford's net worth.

How old is Quentin S. Blackford?

Mr. Blackford is currently 45 years old. There are 5 older executives and no younger executives at iRhythm Technologies. Learn More on Quentin S. Blackford's age.

What is Quentin S. Blackford's salary?

As the CEO of iRhythm Technologies, Inc., Mr. Blackford earns $1,420,000.00 per year. Learn More on Quentin S. Blackford's salary.

How do I contact Quentin S. Blackford?

The corporate mailing address for Mr. Blackford and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Quentin S. Blackford's contact information.

Has Quentin S. Blackford been buying or selling shares of iRhythm Technologies?

During the last quarter, Quentin S. Blackford has sold $1,249,784.45 in iRhythm Technologies stock. Most recently, Quentin S. Blackford sold 16,145 shares of the business's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $77.41, for a transaction totalling $1,249,784.45. Following the completion of the sale, the chief executive officer now directly owns 159,929 shares of the company's stock, valued at $12,380,103.89. Learn More on Quentin S. Blackford's trading history.

Who are iRhythm Technologies' active insiders?

iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.

Are insiders buying or selling shares of iRhythm Technologies?

In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 13 times. They sold a total of 69,024 shares worth more than $7,151,438.22. The most recent insider tranaction occured on December, 2nd when insider Patrick Michael Murphy sold 2,492 shares worth more than $214,037.88. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.

Information on this page was last updated on 12/2/2024.

Quentin S. Blackford Insider Trading History at iRhythm Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2024Sell16,145$77.41$1,249,784.45159,929View SEC Filing Icon  
2/29/2024Sell24,701$121.96$3,012,533.96180,015View SEC Filing Icon  
11/2/2022Sell12,699$122.40$1,554,357.6089,280View SEC Filing Icon  
See Full Table

Quentin S. Blackford Buying and Selling Activity at iRhythm Technologies

This chart shows Quentin S Blackford's buying and selling at iRhythm Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iRhythm Technologies Company Overview

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $90.39
Low: $85.29
High: $91.22

50 Day Range

MA: $80.38
Low: $57.94
High: $91.45

2 Week Range

Now: $90.39
Low: $55.92
High: $124.11

Volume

506,936 shs

Average Volume

465,130 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26